Related Experiment Video
Updated: Jun 17, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Treatment of MDS: something old, something new, something borrowed
1Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA. sekerem@ccf.org
Hematology. American Society of Hematology. Education Program
|December 17, 2009
Summary
Treatment options for myelodysplastic syndromes (MDS) have expanded significantly. New therapies offer improved outcomes for both lower-risk and higher-risk MDS patients, including targeted agents and combination strategies.
Area of Science:
- Hematology
- Oncology
Background:
- The treatment landscape for myelodysplastic syndromes (MDS) has evolved dramatically over the past two decades.
- A wide array of therapeutic options are now available for both lower-risk and higher-risk MDS patient populations.
Purpose of the Study:
- To review current and emerging treatment strategies for myelodysplastic syndromes.
- To highlight advancements in managing lower-risk and higher-risk MDS.
Main Methods:
- Review of recent clinical studies and therapeutic advancements in MDS.
- Analysis of treatment efficacy for various patient subgroups and cytogenetic abnormalities.
- Discussion of novel pathways and combination therapies.
Main Results:
- Erythropoiesis-stimulating agents (ESAs) show survival benefits in lower-risk MDS, with decision tools aiding treatment selection.
- Lenalidomide demonstrates efficacy in specific lower-risk MDS patient groups, particularly with del(5q) abnormality.
- DNA methyltransferase inhibitors (e.g., azacitidine) provide survival advantages in higher-risk MDS compared to conventional treatments.
Conclusions:
- Current MDS therapies offer improved outcomes and survival advantages for both lower- and higher-risk patients.
- Emerging treatments targeting novel pathways and combination strategies represent the future of MDS management.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...